New treatment for joint pain after injuries
Official title: Engineered Biotherapeutic Agent for Treatment of Post-Traumatic Osteoarthritis
Funded at Provizigen LLC · NIH-10821518 · Data updated 2026-11-12
This study is testing a new gel that can be injected into joints to help reduce inflammation and protect cartilage for people who have joint injuries and are at risk of developing post-traumatic osteoarthritis.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Provizigen LLC NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 25, 2023 |
| Project end | August 31, 2026 |
| Funding year | 2023 |
| Award (this year) | $137,260 |
| NIH project number | 1R41AR083738-01 |
| Project ID | NIH-10821518 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have suffered acute joint injuries leading to post-traumatic osteoarthritis.
✕Less likely to help
Patients with chronic osteoarthritis not related to recent joint injuries may not benefit from this research.
What this research studies
This research focuses on developing a novel injectable hydrogel that delivers anti-inflammatory and cartilage-protecting agents directly into the joints affected by post-traumatic osteoarthritis (PTOA). The approach involves using a protein-engineered therapeutic system called HydroGEN, which forms a gel upon injection, allowing for sustained release of the treatment. The goal is to prevent the rapid degeneration of cartilage that occurs after joint injuries and promote natural cartilage repair. Patients who have experienced joint injuries may benefit from this innovative treatment.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option that slows down or halts the progression of post-traumatic osteoarthritis, potentially reducing the need for joint replacement surgeries.
How similar studies have gone: Previous preclinical studies have shown promising results with similar injectable therapies in preventing the development of post-traumatic osteoarthritis.
Where this research is happening
-
Provizigen LLC
New York, United States Active
Researchers
- Principal investigator: Chaugule, Jui Shivaji — Provizigen LLC
- Study coordinator: Chaugule, Jui Shivaji
Related research
Other NIH-funded projects on the same topics.
-
Understanding how knee pain and knee obesity and muscle loss affect knee osteoarthritis
This project looks at how knee swelling, excess knee fat, and muscle loss relate to pain and structural changes in knee osteoarthritis in adults.
-
Identifying OA subtypes and early warning signs before joint damage
This grant asks researchers to find early, invisible clues of osteoarthritis subtypes so we can target treatments before joints are damaged.
-
Digital biomarkers to guide personalized rehab after ACL injury
Aims to use wearable sensors and phone videos to predict early osteoarthritis risk after ACL surgery so rehabilitation can be tailored to each patient.
-
Aberrant mechano-oxygen coupling linked to zinc-rich mineralization in osteoarthritis
Aims to understand how abnormal joint forces affect cartilage and bone, causing zinc-rich mineral deposits and harmful blood vessel growth in osteoarthritis.
-
Notch signaling in TMJ osteoarthritis: uncovering mechanisms and new targets
Researchers are studying how Notch signaling affects TMJ osteoarthritis to identify new ways to protect and repair the jaw joint.
-
Nanoparticles delivering an sPLA2 blocker for knee osteoarthritis
This project uses tiny, drug-filled nanoparticles to deliver an sPLA2-blocking medicine into the knee to reduce inflammation and slow knee osteoarthritis in people with painful knee OA.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.